Results 131 to 140 of about 71,079 (262)

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale   +5 more
wiley   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour   +4 more
wiley   +1 more source

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA)
Hannah Buchbauer   +8 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

open access: yesAddiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock   +8 more
wiley   +1 more source

Next-step treatment for schizophrenia non-responsive to antipsychotics: a systematic review and network meta-analysis. [PDF]

open access: yesEClinicalMedicine
Furukawa Y   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy